[Mengke Pharmaceutical: Signed an exclusive license agreement and platform cooperation agreement for MRX-23 with ClearideBio, with a total payment limit of US$750 million] On October 9, Mengke Pharmaceutical (688373.SH) announced that the company plans to sign an exclusive license agreement and platform technology cooperation agreement for the MRX-23 project with ClearideBio of Switzerland. The former involves the global exclusive license of the MRX-23 project; the latter is a multi-project option cooperation based on the company's independently developed new camptothecin-loaded "STOPIN" antibody-conjugated drug platform. ClearideBio can exercise the option for an agreed number of targets or target combination projects as agreed in the agreement. According to the MRX-23 license agreement, an initial payment of US$1 million will be paid as agreed after the agreement comes into effect. This amount is non-refundable after payment; recent development milestone payments are triggered when the licensed product obtains approval of the clinical trial application for the first time. The total nominal maximum payment limit for MRX-23 R&D, registration and sales milestones is US$223 million, and the total maximum payment limit when all platform cooperation projects are exercised and all milestones are achieved is US$750 million.